Summary
Serum TATI (tumor-associated trypsin inhibitor) was measured in 41 control subjects, 30 patients with pancreatic cancer, 53 with chronic pancreatitis, and 47 with extrapancreatic diseases, mainly of gastrointestinal origin. TATI was found to be elevated in some subjects in all groups of patients; patients with chronic pancreatitis studied during an acute exacerbation of the disease had the highest percentage (68%) of pathological values. TATI was found to be correlated with elastase 1, tissue polypeptide antigen, and total and pancreatic isoamylase. A significant relationship was also found between TATI and serum creatinine levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- TATI:
-
Tumor-associated trypsin inhibitor
- PSTI:
-
Pancreatic secretory trypsin inhibitor
- TPA:
-
Tissue polypeptide antigen
References
Cubilla AL, Fitzgerald PJ (1978) Pancreas cancer. 1. Duct adenocarcinoma. Pathol Annu 13:241–289
Eddeland A, Ohlsson K (1978) A radioimmunoassay for measurement of human pancreatic secretory trypsin inhibitor in different body fluids. Hoppe-Seyler's Z Physiol Chem 359:671–675
Haglund C, Huhtala M-L, Halila H, Nordling S, Roberts PJ, Scheinin TM, Stenman U-H (1986) Tumor-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 54:297–303
Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H (1982) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257:13713–13716
Huhtala M-L, Kahanpaa K, Seppala M, Halila H, Stenman U-H (1983) Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 31:711–714
Kitahara T, Takatsuka Y, Fujimoto K-I, Tanaka S, Ogawa M, Kosaki G (1980) Radioimmunoassay for human pancreatic secretory trypsin inhibitor: measurement of serum pancreatic secretory trypsin inhibitor in normal subjects and subjects with pancreatic diseases. Clin Chim Acta 103:135–143
Laskowski M, Kato I (1980) Protein inhibitors of proteinases. Ann Rev Biochem 49:593–626
Kolho K-L, Huhtala M-L, Jalanko H, Rauramo I, Stenman U-H (1986) Pancreatic secretory trypsin inhibitor from human amniotic fluid and fetal and neonatal urine: concentrations and physicochemical characterization. Clin Chim Acta 156:123–130
Marks WH, Ohlsson K (1983) Elimination of pancreatic secretory trypsin inhibitor from the circulation. Scand J Gastroenterol 18:955–959
Otsuki M, Oka T, Suchiro I, Okabayashi Y, Ohki A, Yuu H, Baba S (1984) Serum pancreatic secretory trypsin inhibitor in pancreatic disease. Clin Chim Acta 142:231–240
Rauscher E, Neuman U, Schaich E, Bulow S, Wahlefeld AW (1985) Optimized conditions for determining activity concentration of α-amylase in serum, with 1,4-α-D-4-nitrophylmaltoheptaoside as substrate. Clin Chem 31:14–19
Tietz NW, Burlina A, Berhardt W, Junge W, Malfertheiner P, Murai T, Ote M, Stein W, Gerber M, Klein G, Poppe WA (1988) Multicentric evaluation of a specific pancreatic isoamylase assay based on a double monoclonal-antibody technique. Clin Chem 34:2096–2102
Wallenstein S, Zucker CL, Fleiss JL (1980) Some statistical methods useful in circulation research. Circ Res 47:1–9
Author information
Authors and Affiliations
Additional information
Supported in part by Centro Regionale di Alta Specializzazione per lo Studio delle Malattie del Fegato e del Pancreas; under the auspices of the R. Farini Association for Gastroenterological Research
Rights and permissions
About this article
Cite this article
Plebani, M., Basso, D., Fabris, C. et al. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases. Klin Wochenschr 67, 1029–1032 (1989). https://doi.org/10.1007/BF01727004
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727004